Epilepsia

Article	Citations
International League Against Epilepsy classification and definition of epilepsy syndromes with onset in childhood: Position paper by the ILAE Task Force on Nosology and Definitions	266
ILAE classification and definition of epilepsy syndromes with onset in neonates and infants: Position statement by the ILAE Task Force on Nosology and Definitions	249
New onset acute symptomatic seizure and risk factors in coronavirus disease 2019: A retrospective multicenter study	210
ILAE definition of the Idiopathic Generalized Epilepsy Syndromes: Position statement by the ILAE Task Force on Nosology and Definitions	161
The ILAE classification of seizures and the epilepsies: Modification for seizures in the neonate. Position paper by the ILAE Task Force on Neonatal Seizures	156
Acute symptomatic seizures secondary to autoimmune encephalitis and autoimmune‐associated epilepsy: Conceptual definitions	143
The SANTÉ study at 10 years of follow‐up: Effectiveness, safety, and sudden unexpected death in epilepsy	136
A new era in electroencephalographic monitoring? Subscalp devices for ultra–long‐term recordings	113
Severe psychological distress among patients with epilepsy during the COVID‐19 outbreak in southwest China	103
The ILAE consensus classification of focal cortical dysplasia: An update proposed by an ad hoc task force of the ILAE diagnostic methods commission	101
Cenobamate (YKP3089) as adjunctive treatment for uncontrolled focal seizures in a large, phase 3, multicenter, open‐label safety study	101
Methodology for classification and definition of epilepsy syndromes with list of syndromes: Report of the ILAE Task Force on Nosology and Definitions	94
International League Against Epilepsy classification and definition of epilepsy syndromes with onset at a variable age: position statement by the ILAE Task Force on Nosology and Definitions	86
Real‐world experience with direct brain‐responsive neurostimulation for focal onset seizures	77
COVID‐19 outbreak: The impact of stress on seizures in patients with epilepsy	75
Epilepsy and brain network hubs	75
Clinical sequencing yield in epilepsy, autism spectrum disorder, and intellectual disability: A systematic review and meta‐analysis	75
Machine learning from wristband sensor data for wearable, noninvasive seizure forecasting	73
Cannabidiol efficacy and clobazam status: A systematic review and meta‐analysis	67
International consensus on diagnosis and management of Dravet syndrome	66
Machine learning and wearable devices of the future	64
The accuracy of using administrative healthcare data to identify epilepsy cases: A systematic review of validation studies	63
Functional connectome contractions in temporal lobe epilepsy: Microstructural underpinnings and predictors of surgical outcome	63
Value of 7T MRI and post‐processing in patients with nonlesional 3T MRI undergoing epilepsy presurgical evaluation	60
Seizure detection using wearable sensors and machine learning: Setting a benchmark	59

Seizure detection at home: Do devices on the market match the needs of people living with epilepsy and their caregivers?	59
Use of ketogenic diet therapy in infants with epilepsy: A systematic review and meta‐analysis	59
COVID‐19 and seizures: Is there a link?	58
The postictal state — What do we know?	58
Continuous EEG findings in patients with COVID‐19 infection admitted to a New York academic hospital system	57
Utility of genetic testing for therapeutic decision‐making in adults with epilepsy	57
Orbitofrontal involvement in a neuroCOVID‐19 patient	56
Deep brain stimulation targets in epilepsy: Systematic review and meta‐analysis of anterior and centromedian thalamic nuclei and hippocampus	56
Comparison of minimally invasive and traditional surgical approaches for refractory mesial temporal lobe epilepsy: A systematic review and meta‐analysis of outcomes	56
Toward a better definition of focal cortical dysplasia: An iterative histopathological and genetic agreement trial	55
Long‐term safety and efficacy of add‐on cannabidiol in patients with Lennox–Gastaut syndrome: Results of a long‐term open‐label extension trial	53
Genetic testing for the epilepsies: A systematic review	53
Connectome biomarkers of drug‐resistant epilepsy	51
Defining Dravet syndrome: An essential pre‐requisite for precision medicine trials	50
Precision medicine for genetic epilepsy on the horizon: Recent advances, present challenges, and suggestions for continued progress	50
Trait and state interoceptive abnormalities are associated with dissociation and seizure frequency in patients with functional seizures	50
Reduced synaptic vesicle protein 2A binding in temporal lobe epilepsy: A [11C]UCB‐J positron emission tomography study	50
Timing of referral to evaluate for epilepsy surgery: Expert Consensus Recommendations from the Surgical Therapies Commission of the International League Against Epilepsy	49
Seizure forecasting and cyclic control of seizures	49
Post–COVID‐19 inflammatory syndrome manifesting as refractory status epilepticus	49
Add‐on cannabidiol in patients with Dravet syndrome: Results of a long‐term open‐label extension trial	48
Automated seizure detection using wearable devices: A clinical practice guideline of the International League Against Epilepsy and the International Federation of Clinical Neurophysiology	47
Cognitive phenotypes in temporal lobe epilepsy utilizing data‐ and clinically driven approaches: Moving toward a new taxonomy	47
Pilot study of focused ultrasound for drug‐resistant epilepsy	47
Epilepsy care during the COVID‐19 pandemic	47
Seizure‐onset regions demonstrate high inward directed connectivity during resting‐state: An SEEG study in focal epilepsy	47
Inflammation, ictogenesis, and epileptogenesis: An exploration through human disease	46
Final results from a Phase 3, long‐term, open‐label, repeat‐dose safety study of diazepam nasal spray for seizure clusters in patients with epilepsy	46
International consensus recommendations for management of new onset refractory status epilepticus including febrile infection‐related epilepsy syndrome: Statements and supporting evidence	46
Progress report on new antiepileptic drugs: A summary of the Fifteenth Eilat Conference on New Antiepileptic Drugs and Devices (EILAT XV). II. Drugs in more advanced clinical development	45
Cross talk between drug‐resistant epilepsy and the gut microbiome	45
Clinical implications of trials investigating drug‐drug interactions between cannabidiol and enzyme inducers or inhibitors or common antiseizure drugs	45
Fenfluramine HCl (Fintepla®) provides long‐term clinically meaningful reduction in seizure frequency: Analysis of an ongoing open‐label extension study	45
Does cannabidiol have antiseizure activity independent of its interactions with clobazam? An appraisal of the evidence from randomized controlled trials	42
Focal to bilateral tonic–clonic seizures are associated with widespread network abnormality in temporal lobe epilepsy	41
International consensus recommendations for management of new onset refractory status epilepticus (NORSE) including febrile infection‐related epilepsy syndrome (FIRES): Summary and clinical tools	41
The ups and downs of alkyl‐carbamates in epilepsy therapy: How does cenobamate differ?	40
Patterns of benzodiazepine underdosing in the Established Status Epilepticus Treatment Trial	40
Signal quality and patient experience with wearable devices for epilepsy management	39
Dietary medium chain triglycerides for management of epilepsy: New data from human, dog, and rodent studies	39
Atlas of lesion locations and postsurgical seizure freedom in focal cortical dysplasia: A MELD study	38
Neurostimulation in people with drug‐resistant epilepsy: Systematic review and meta‐analysis from the ILAE Surgical Therapies Commission	38
Cenobamate (XCOPRI): Can preclinical and clinical evidence provide insight into its mechanism of action?	38
Genetic epilepsies and COVID‐19 pandemic: Lessons from the caregiver perspective	37
Temporal lobe regions essential for preserved picture naming after left temporal epilepsy surgery	37
Microglia proliferation plays distinct roles in acquired epilepsy depending on disease stages	37
Efficacy and safety of Fenfluramine hydrochloride for the treatment of seizures in Dravet syndrome: A real‐world study	37
COVID‐19 vaccine take‐up rate and safety in adults with epilepsy: Data from a multicenter study in China	37
Long‐term cannabidiol treatment for seizures in patients with tuberous sclerosis complex: An open‐label extension trial	37
Incidence and prevalence of psychogenic nonepileptic seizures in a Norwegian county: A 10‐year population‐based study	37

Seizure control, stress, and access to care during the COVID‐19 pandemic in New York City: The patient perspective	36
The global cost of epilepsy: A systematic review and extrapolation	36
Deciphering the surgical treatment gap for drug‐resistant epilepsy (DRE): A literature review	35
First evidence of altered microbiota and intestinal damage and their link to absence epilepsy in a genetic animal model, the WAG/Rij rat	35
Trends in the use of automated algorithms for the detection of high‐frequency oscillations associated with human epilepsy	35
The severe epilepsy syndromes of infancy: A population‐based study	35
Systematic review of frequency of felt and enacted stigma in epilepsy and determining factors and attitudes toward persons living with epilepsy—Report from the International League Against Epilepsy Ta	35
Accurate detection of typical absence seizures in adults and children using a two‐channel electroencephalographic wearable behind the ears	34
Precision medicine and therapies of the future	34
Phenobarbital and midazolam suppress neonatal seizures in a noninvasive rat model of birth asphyxia, whereas bumetanide is ineffective	34
Neonatal presentation of genetic epilepsies: Early differentiation from acute provoked seizures	34
Biomarkers of seizure response to vagus nerve stimulation: A scoping review	34
First‐line antiepileptic drug treatment in glioma patients with epilepsy: Levetiracetam vs valproic acid	33
Postinjury weight rather than cognitive or behavioral impairment predicts development of posttraumatic epilepsy after lateral fluid‐percussion injury in rats	33
The worldwide epilepsy treatment gap: A systematic review and recommendations for revised definitions – A report from the ILAE Epidemiology Commission	33
Lessons learned from 40 novel PIGA patients and a review of the literature	33
Carbon emission savings and short‐term health care impacts from telemedicine: An evaluation in epilepsy	33
Temporal lobe epilepsy surgery in children and adults: A multicenter study	33
A pragmatic algorithm to select appropriate antiseizure medications in patients with epilepsy	33
Visually sensitive seizures: An updated review by the Epilepsy Foundation	32
Neonatal developmental and epileptic encephalopathy due to autosomal recessive variants in SLC13A5 gene	32
Detection of brain somatic variation in epilepsy‐associated developmental lesions	32
External validation of automated focal cortical dysplasia detection using morphometric analysis	32
Epileptic heart: A clinical syndromic approach	32
Stereotactic MRI‐guided laser interstitial thermal therapy for extratemporal lobe epilepsy	32
Anterior nucleus of the thalamus seizure detection in ambulatory humans	31
Epilepsy, antiepileptic drugs, and the risk of major cardiovascular events	31
Cardiovascular safety of fenfluramine in the treatment of Dravet syndrome: Analysis of an ongoing long‐term open‐label safety extension study	31
Design and implementation of electronic health record common data elements for pediatric epilepsy: Foundations for a learning health care system	31
SCN2A‐Developmental and Epileptic Encephalopathies: Challenges to trial‐readiness for non‐seizure outcomes	31
Prediction of seizure recurrence risk following discontinuation of antiepileptic drugs	30
Prevalence and incidence of epilepsy in Latin America and the Caribbean: A systematic review and meta‐analysis of population‐based studies	30
Overcoming the challenges of developing an intranasal diazepam rescue therapy for the treatment of seizure clusters	30
Temporal variability profiling of the default mode across epilepsy subtypes	30
Astrocyte and glutamate involvement in the pathogenesis of epilepsy in Alzheimer's disease	30
Virtual epileptic patient brain modeling: Relationships with seizure onset and surgical outcome	30
Phenotypic and genetic spectrum of epilepsy with myoclonic atonic seizures	30
Soticlestat, a novel cholesterol 24‐hydroxylase inhibitor, reduces seizures and premature death in Dravet syndrome mice	30
Practical considerations in epilepsy neurostimulation	30
ILAE clinical practice recommendations for the medical treatment of depression in adults with epilepsy	30
Persistent treatment resistance in genetic generalized epilepsy: A long‐term outcome study in a tertiary epilepsy center	30
Neurovascular unit dysfunction as a mechanism of seizures and epilepsy during aging	29
Blood biomarkers predictive of epilepsy after an acute stroke event	29
Altered communication dynamics reflect cognitive deficits in temporal lobe epilepsy	29
On seizure semiology	28
Effectiveness and safety of perampanel monotherapy for focal and generalized tonic‐clonic seizures: Experience from a national multicenter registry	28
Hemispherectomy Outcome Prediction Scale: Development and validation of a seizure freedom prediction tool	28
Tensor‐valued diffusion MRI differentiates cortex and white matter in malformations of cortical development associated with epilepsy	28
The power of ECG in multimodal patient‐specific seizure monitoring: Added value to an EEG‐based detector using limited channels	27
Intracranial electroencephalographic biomarker predicts effective responsive neurostimulation for epilepsy prior to treatment	27
Effect of combined physical training on cognitive function in people with epilepsy: Results from a randomized controlled trial	27
A phase 2, randomized, double‐blind, placebo‐controlled study to evaluate the efficacy and safety of soticlestat as adjunctive therapy in pediatric patients with Dravet syndrome or Lennox–Gastaut synd	27
Value of smartphone videos for diagnosis of seizures: Everyone owns half an epilepsy monitoring unit	27
Neocortical injury–induced status epilepticus	27
CDKL5 deficiency in forebrain glutamatergic neurons results in recurrent spontaneous seizures	27
A perspective on the physicochemical and biopharmaceutic properties of marketed antiseizure drugs—From phenobarbital to cenobamate and beyond	27
The road to a World Health Organization global action plan on epilepsy and other neurological disorders	27
Improving the prediction of epilepsy surgery outcomes using basic scalp EEG findings	27
Focal nonmotor versus motor seizures: The impact on diagnostic delay in focal epilepsy	27
Interictal intracranial electroencephalography for predicting surgical success: The importance of space and time	27
Efficacy of cenobamate for uncontrolled focal seizures: Post hoc analysis of a Phase 3, multicenter, open‐label study	26
Perampanel and pregnancy	26
Are AI language models such as ChatGPT ready to improve the care of individuals with epilepsy?	26
Genes4Epilepsy: An epilepsy gene resource	26
Progress report on new antiepileptic drugs: A summary of the Fifteenth Eilat Conference on New Antiepileptic Drugs and Devices (EILAT XV). I. Drugs in preclinical and early clinical development	26
Molecular and clinical descriptions of patients with GABAA receptor gene variants (GABRA1, GABRB2, GABRB3, GABRG2): A cohort st	26
Atypical functional connectome hierarchy impacts cognition in temporal lobe epilepsy	26
A hypothesis for the role of axon demyelination in seizure generation	26
Development of an antiseizure drug screening platform for Dravet syndrome at the NINDS contract site for the Epilepsy Therapy Screening Program	25
Noninvasive mobile EEG as a tool for seizure monitoring and management: A systematic review	25
Systematic analysis and comparison of commercial seizure‐detection software	25
Interictal electroencephalographic functional network topology in drug‐resistant and well‐controlled idiopathic generalized epilepsy	25
Twenty‐four‐hour patterns in electrodermal activity recordings of patients with and without epileptic seizures	25
Peri‐ictal hypoxia is related to extent of regional brain volume loss accompanying generalized tonic‐clonic seizures	25
Convulsive seizures and some behavioral comorbidities are uncoupled in the Scn1aA1783V Dravet syndrome mouse model	25
The role of new medical treatments for the management of developmental and epileptic encephalopathies: Novel concepts and results	25
Automated seizure detection with noninvasive wearable devices: A systematic review and meta‐analysis	25
The development of an epilepsy electronic patient portal: Facilitating both patient empowerment and remote clinician‐patient interaction in a post‐COVID‐19 world	25
Comorbidities in patients with epilepsy: Frequency, mechanisms and effects on long‐term outcome	25
Treatment of psychogenic nonepileptic seizures (PNES) using video telehealth	25

Increased frequency of proinflammatory CD4 T cells and pathological levels of serum neurofilament light chain in adult drug‐resistant epilepsy	24
Introduction to the epilepsy syndrome papers	24
Seizure detection using heart rate variability: A prospective validation study	24
Wearable devices for seizure detection: Practical experiences and recommendations from the Wearables for Epilepsy And Research (WEAR) International Study Group	24
Physical activity in people with epilepsy: A systematic review	24
Big data in epilepsy: Clinical and research considerations. Report from the Epilepsy Big Data Task Force of the International League Against Epilepsy	24
Seizures with paroxysmal arousals in sleep‐related hypermotor epilepsy (SHE): Dissecting epilepsy from NREM parasomnias	24
Epilepsy syndromes, etiologies, and the use of next‐generation sequencing in epilepsy presenting in the first 2 years of life: A population‐based study	24
Post hoc analysis of a phase 3, multicenter, open‐label study of cenobamate for treatment of uncontrolled focal seizures: Effects of dose adjustments of concomitant antiseizure medications	24
A physiologically validated rat model of term birth asphyxia with seizure generation after, not during, brain hypoxia	24
Intravenous ganaxolone for the treatment of refractory status epilepticus: Results from an open‐label, dose‐finding, phase 2 trial	24
Early‐life epilepsy after acute symptomatic neonatal seizures: A prospective multicenter study	24
Resting‐state functional magnetic resonance imaging with independent component analysis for presurgical seizure onset zone localization: A systematic review and meta‐analysis	24
Seizures in autoimmune encephalitis—A systematic review and quantitative synthesis	24
Correcting for physiological ripples improves epileptic focus identification and outcome prediction	24
Norwegian population‐based study of long‐term effects, safety, and predictors of response of vagus nerve stimulation treatment in drug‐resistant epilepsy: The NORPulse study	23
Long‐term safety of adjunctive cenobamate in patients with uncontrolled focal seizures: Open‐label extension of a randomized clinical study	23
Signal quality and power spectrum analysis of remote ultra long‐term subcutaneous EEG	23
Disruption of intestinal barrier and endotoxemia after traumatic brain injury: Implications for post‐traumatic epilepsy	23
Cycles of self‐reported seizure likelihood correspond to yield of diagnostic epilepsy monitoring	23
Can we use intraoperative high‐frequency oscillations to guide tumor‐related epilepsy surgery?	23
Cortex leads the thalamic centromedian nucleus in generalized epileptic discharges in Lennox‐Gastaut syndrome	23
The role of surgery in the management of Lennox–Gastaut syndrome: A systematic review and meta‐analysis of the clinical evidence	22
Clinical presentation of new onset refractory status epilepticus in children (the pSERG cohort)	22
Multicenter, cross‐sectional study of the costs of illness and cost‐driving factors in adult patients with epilepsy	22
Neurodevelopmental outcomes in children exposed to newer antiseizure medications: A systematic review	22
Epilepsy surgery in infants up to 3 months of age: Safety, feasibility, and outcomes: A multicenter, multinational study	22
The epilepsy–autism spectrum disorder phenotype in the era of molecular genetics and precision therapy	22
Predicting mood decline following temporal lobe epilepsy surgery in adults	22
Accurate identification of EEG recordings with interictal epileptiform discharges using a hybrid approach: Artificial intelligence supervised by human experts	22
Quantitative analysis of hyperkinetic seizures and correlation with seizure onset zone	22
Identifying seizure risk factors: A comparison of sleep, weather, and temporal features using a Bayesian forecast	21
Efficacy, tolerability, and retention of fenfluramine for the treatment of seizures in patients with Dravet syndrome: Compassionate use program in Germany	21
Zebrafish model of posttraumatic epilepsy	21
Collaborative Cross mice reveal extreme epilepsy phenotypes and genetic loci for seizure susceptibility	21
Reduced expression of the glucocorticoid receptor in the hippocampus of patients with drug‐resistant temporal lobe epilepsy and comorbid depression	21
Elevated blood purine levels as a biomarker of seizures and epilepsy	21
Fenfluramine significantly reduces day‐to‐day seizure burden by increasing number of seizure‐free days and time between seizures in patients with Dravet syndrome: A time‐to‐event analysis	21
Distinct epilepsy phenotypes and response to drugs in KCNA1 gain‐ and loss‐of function variants	21
Digital conversations about suicide among teenagers and adults with epilepsy: A big‐data, machine learning analysis	21
Clinical and EEG factors associated with antiseizure medication resistance in idiopathic generalized epilepsy	21
Systemic administration of ivabradine, a hyperpolarization‐activated cyclic nucleotide‐gated channel inhibitor, blocks spontaneous absence seizures	20
Sudden unexpected death in epilepsy in persons younger than 50 years: A retrospective nationwide cohort study in Denmark	20
Early epileptiform EEG activity in infants with tuberous sclerosis complex predicts epilepsy and neurodevelopmental outcomes	20
Provoked seizures and status epilepticus in a pediatric population with COVID‐19 disease	20
Inflammatory and neurotrophic factor plasma levels are related to epilepsy independently of etiology	20
Effect of fenfluramine on convulsive seizures in CDKL5 deficiency disorder	20
Biomarkers of seizure severity derived from wearable devices	20
Utility of 18F‐fluorodeoxyglucose positron emission tomography in presurgical evaluation of patients with epilepsy: A multicenter study	20
Treatment of seizures in the neonate: Guidelines and consensus‐based recommendations—Special report from the ILAE Task Force on Neonatal Seizures	20
Cost‐effectiveness of adrenocorticotropic hormone versus oral steroids for infantile spasms	20
Long‐term seizure outcomes in patients with autoimmune encephalitis: A prospective observational registry study update	19
Reply to the commentary by Ben‐Ari and Delpire: Bumetanide and neonatal seizures: Fiction versus reality	19
Reasons for not having epilepsy surgery	19
Antiepileptic combination therapy with Stevens‐Johnson syndrome and toxic epidermal necrolysis: Analysis of a Japanese pharmacovigilance database	19
Vascular risk factors as predictors of epilepsy in older age: The Framingham Heart Study	19
Diagnosing cognitive disorders in older adults with epilepsy	19
Absence seizures and their relationship to depression and anxiety: Evidence for bidirectionality	19
The long‐term efficacy of cannabidiol in the treatment of refractory epilepsy	19
Establishing criteria for pediatric epilepsy surgery center levels of care: Report from the ILAE Pediatric Epilepsy Surgery Task Force	19
Long‐term individual retention with cenobamate in adults with focal seizures: Pooled data from the clinical development program	19
Which seizure elements do patients memorize? A comparison of history and seizure documentation	19
Cues for seizure timing	19
Long‐term chemogenetic suppression of seizures in a multifocal rat model of temporal lobe epilepsy	19
Seizure activity triggers tau hyperphosphorylation and amyloidogenic pathways	19
The timelines of MRI findings related to outcomes in adult patients with new‐onset refractory status epilepticus	19
Motor hyperactivation during cognitive tasks: An endophenotype of juvenile myoclonic epilepsy	18
A combination of phenobarbital and the bumetanide derivative bumepamine prevents neonatal seizures and subsequent hippocampal neurodegeneration in a rat model of birth asphyxia	18
Developmental and epilepsy spectrum of KCNB1 encephalopathy with long‐term outcome	18
Cell death of hippocampal CA1 astrocytes during early epileptogenesis	18
Drug resistance in idiopathic generalized epilepsies: Evidence and concepts	18
Long‐term seizure outcome during continuous bipolar hippocampal deep brain stimulation in patients with temporal lobe epilepsy with or without mesial temporal sclerosis: An observational, open‐label s	18
Evaluation of subchronic administration of antiseizure drugs in spontaneously seizing rats	18
Long‐term efficacy, tolerability, and retention of brivaracetam in epilepsy treatment: A longitudinal multicenter study with up to 5 years of follow‐up	18
Stereotactic Laser Ablation for Mesial Temporal Lobe Epilepsy: A prospective, multicenter, single‐arm study	18
Time to onset of cannabidiol (CBD) treatment effect in Lennox–Gastaut syndrome: Analysis from two randomized controlled trials	18
Patient‐specific structural connectivity informs outcomes of responsive neurostimulation for temporal lobe epilepsy	18
Epilepsy with myoclonic‐atonic seizures (Doose syndrome): Clarification of diagnosis and treatment options through a large retrospective multicenter cohort	18
Bridging the gap in epilepsy care: A single‐center experience of 3700 outpatient tele‐epilepsy visits	18
Outcomes of children and adolescents 1 year after being seen in a multidisciplinary psychogenic nonepileptic seizures clinic	18
Assessing seizure burden in pediatric epilepsy using an electronic medical record–based tool through a common data element approach	18
Minimum standards for inpatient long‐term video‐electroencephalographic monitoring: A clinical practice guideline of the International League Against Epilepsy and International Federation of Clinical	18
Adjunctive everolimus therapy for tuberous sclerosis complex‐associated refractory seizures: Results from the postextension phase of EXIST‐3	18
Association between antiseizure medications and quality of life in epilepsy: A mediation analysis	18
Transforming epilepsy research: A systematic review on natural language processing applications	18
Neurostimulation in generalized epilepsy: A systematic review and meta‐analysis	17
Tofacitinib treatment for refractory autoimmune encephalitis	17
Past, Present and Future of Home video‐electroencephalographic telemetry: A review of the development of in‐home video‐electroencephalographic recordings	17
Effects of lacosamide and carbamazepine on lipids in a randomized trial	17
Prolonged epileptic discharges predict seizure recurrence in JME: Insights from prolonged ambulatory EEG	17
High‐mobility group box 1 as a predictive biomarker for drug‐resistant epilepsy: A proof‐of‐concept study	17
Stereotactic laser anterior corpus callosotomy for Lennox‐Gastaut syndrome	17
Adjunctive cenobamate in highly active and ultra‐refractory focal epilepsy: A “real‐world” retrospective study	17
Changes in cognition after introduction or withdrawal of zonisamide versus topiramate in epilepsy patients: A retrospective study using Bayes statistics	17
Functional and behavioral signatures of Kv7 activator drug subtypes	17